BACKGROUND: general opinion is growing that drug cessation in complex older patients is warranted in certain situations. From a clinical viewpoint, drug cessation seems most warranted in four situations, i.e., falls, delirium, cognitive impairment and end-of-life situations. To date, little information about the effects of drug cessation in these four situations is available. OBJECTIVES: to identify the effects and effectiveness of drug cessation on falls, delirium and cognitive impairment. For end-of-life situations, we reviewed cessation of inappropriate drug use. METHODS: electronic databases were searched using MeSH terms and relevant keywords. Studies published in English were included if they evaluated the effects of drug cessation in older persons, aged ≥65 years, with falls, delirium or cognitive impairment; or cessation of inappropriate drug use in end-of-life situations. RESULTS: we selected seven articles for falls, none for delirium, two for cognition and two for end-of-life situations. Withdrawal of psychotropics reduced fall rate; a prescribing modification programme for primary care physicians reduced fall risk. Withdrawal of psychotropics and a systematic reduction of polypharmacy resulted in an improvement of cognition. Very little rigorous research has been conducted on reducing inappropriate medications in patients approaching end of life. CONCLUSION: little research has focussed on drug cessation. Available studies showed a beneficial impact of cessation of psychotropic drugs on falls and cognitive status. More research in this field is needed. The issue of systematic drug withdrawal in end-of-life cases is controversial, but is increasingly relevant in the face of rising numbers of older people of this clinical status.
BACKGROUND: general opinion is growing that drug cessation in complex older patients is warranted in certain situations. From a clinical viewpoint, drug cessation seems most warranted in four situations, i.e., falls, delirium, cognitive impairment and end-of-life situations. To date, little information about the effects of drug cessation in these four situations is available. OBJECTIVES: to identify the effects and effectiveness of drug cessation on falls, delirium and cognitive impairment. For end-of-life situations, we reviewed cessation of inappropriate drug use. METHODS: electronic databases were searched using MeSH terms and relevant keywords. Studies published in English were included if they evaluated the effects of drug cessation in older persons, aged ≥65 years, with falls, delirium or cognitive impairment; or cessation of inappropriate drug use in end-of-life situations. RESULTS: we selected seven articles for falls, none for delirium, two for cognition and two for end-of-life situations. Withdrawal of psychotropics reduced fall rate; a prescribing modification programme for primary care physicians reduced fall risk. Withdrawal of psychotropics and a systematic reduction of polypharmacy resulted in an improvement of cognition. Very little rigorous research has been conducted on reducing inappropriate medications in patients approaching end of life. CONCLUSION: little research has focussed on drug cessation. Available studies showed a beneficial impact of cessation of psychotropic drugs on falls and cognitive status. More research in this field is needed. The issue of systematic drug withdrawal in end-of-life cases is controversial, but is increasingly relevant in the face of rising numbers of older people of this clinical status.
Entities:
Keywords:
cognitive impairment; delirium; drug cessation; end of life; falls; older adults; older people
Authors: Farhad Pazan; Heinrich Burkhardt; Helmut Frohnhofen; Christel Weiss; Christina Throm; Alexandra Kuhn-Thiel; Martin Wehling Journal: Drugs Aging Date: 2019-03 Impact factor: 3.923
Authors: Marcia C Mecca; John M Thomas; Kristina M Niehoff; Anne Hyson; Sean M Jeffery; John Sellinger; Adam P Mecca; Peter H Van Ness; Terri R Fried; Rebecca Brienza Journal: J Gen Intern Med Date: 2019-04-10 Impact factor: 5.128
Authors: Xavier Vidal; Antonia Agustí; Antoni Vallano; Francesc Formiga; Antonio Fernández Moyano; Juana García; Alfonso López-Soto; Nieves Ramírez-Duque; Olga H Torres; José Barbé; Antonio San-José Journal: Eur J Clin Pharmacol Date: 2016-03-05 Impact factor: 2.953
Authors: Andreas D Meid; Renate Quinzler; Andreas Groll; Beate Wild; Kai-Uwe Saum; Ben Schöttker; Dirk Heider; Hans-Helmut König; Hermann Brenner; Walter E Haefeli Journal: Eur J Clin Pharmacol Date: 2016-03-29 Impact factor: 2.953